^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Cancer

    Related cancers:
    1d
    LUNGDOC: Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis (clinicaltrials.gov)
    P=N/A, N=133, Active, not recruiting, University Hospital, Montpellier | Trial completion date: Jul 2025 --> Dec 2026
    Trial completion date
    1d
    Holistic Acupuncture for Patients With Chemotherapy Induced Nausea (clinicaltrials.gov)
    P=N/A, N=90, Recruiting, Vejle Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial
    1d
    Identification of Palliative Care Needs and Prognostic Factors of Survival in Tailoring Appropriate Interventions in Advanced Oncological, Renal and Pulmonary Diseases (clinicaltrials.gov)
    P=N/A, N=178, Completed, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Active, not recruiting --> Completed
    Trial completion
    1d
    NRG-LU005: Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov)
    P3, N=544, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2029
    Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV
    1d
    KEYNOTE D46: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) (clinicaltrials.gov)
    P3, N=614, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    1d
    Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) (clinicaltrials.gov)
    P1/2, N=315, Active, not recruiting, Dizal Pharmaceuticals | Trial completion date: Jul 2025 --> Dec 2025
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Zegfrovy (sunvozertinib)
    1d
    A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    1d
    Revealing Causal Protein Biomarkers and Potential Therapeutic Targets for Histologic-Specific Lung Cancer. (PubMed, J Cell Mol Med)
    Tier 3 proteins, supported by logistic regression and MR only, included CD5L, GNPDA, ACAN, C7, DMP1, HEPH, CEACAM6, COX6B1, CPXM2 and IL12RB2. Druggability evaluation suggests that existing drugs targeting ITGB2, GP1BA, ACADSB and COX6B1 could potentially be repurposed for the treatment of specific lung cancer subtypes.
    Journal
    |
    CEACAM6 (CEA Cell Adhesion Molecule 6) • ITGB2 (Integrin Subunit Beta 2) • ACAN (Aggrecan) • AGRN (Agrin) • ACADSB (Acyl-CoA Dehydrogenase Short/Branched Chain)
    1d
    The role and mechanism of ARRB1 in simulated space radiation and microgravity-induced lung carcinogenesis. (PubMed, NPJ Microgravity)
    ARRB1 nuclear translocation enhances CA9 transcriptional activity following simulated space radiation and/or microgravity exposure. In short, changes in intracellular calcium concentration play a crucial role in ARRB1 nuclear translocation and subsequent malignant transformation.
    Journal
    |
    CA9 (Carbonic anhydrase 9) • ARRB1 (Arrestin Beta 1)
    1d
    Profound neutrophilia as the presenting sign of GCSF-secreting, ROS1-mutant squamous cell lung cancer. (PubMed, BMJ Case Rep)
    Furthermore, this case describes a rare presentation of a ROS1 alteration in SCC of the lung. This illustrates the importance of routine comprehensive genomic profiling in lung cancer patients regardless of histology and smoking status.
    Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 rearrangement
    1d
    SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities. (PubMed, Cancer Lett)
    We also critically examine the shortcomings of early-generation SRC inhibitors in solid tumors and highlight emerging therapeutic avenues such as next-generation inhibitors, proteolysis-targeting chimera (PROTAC) degraders, and biomarker-guided combination strategies. By connecting molecular insights with preclinical and clinical findings, this review positions SRC as a therapeutically actionable vulnerability in KRAS-driven cancers and outlines a translational framework for overcoming drug resistance.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C